On July 18, 2025, Jefferies analyst Andrew Tsai initiated coverage on Stoke Therapeutics (STOK, Financial) with a "Buy" rating. This move marks a significant development for the biopharmaceutical company as it continues to focus on advancing its clinical programs.
The initiation of coverage comes with a price target announcement of USD 30.00 for Stoke Therapeutics (STOK, Financial). This price target underscores the analyst's optimistic outlook on the company's potential to deliver shareholder value through its ongoing and future projects.
Stoke Therapeutics (STOK, Financial), which trades on the NASDAQ exchange, gains attention in the market following this favorable analyst rating. Investors and market watchers are likely to keep a close eye on the stock as it develops further.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Stoke Therapeutics Inc (STOK, Financial) is $22.38 with a high estimate of $35.00 and a low estimate of $15.00. The average target implies an upside of 81.17% from the current price of $12.35. More detailed estimate data can be found on the Stoke Therapeutics Inc (STOK) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Stoke Therapeutics Inc's (STOK, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Stoke Therapeutics Inc (STOK, Financial) in one year is $51.48, suggesting a upside of 316.84% from the current price of $12.35. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Stoke Therapeutics Inc (STOK) Summary page.
